Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 Studies.

Morgan, Erin S; Tami, Yvonne; Hu, Kuolung; Brambatti, Michela; Mullick, Adam E; Geary, Richard S; Bakris, George L; Tsimikas, Sotirios

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L_Rx: Results of Phase 1 and Phase 2 Studies.

Morgan, Erin S; Tami, Yvonne; Hu, Kuolung; Brambatti, Michela; Mullick, Adam E; Geary, Richard S; Bakris, George L; Tsimikas, Sotirios.

Afiliación

Morgan ES; Ionis Pharmaceuticals, Carlsbad, California, USA.
Tami Y; Ionis Pharmaceuticals, Carlsbad, California, USA.
Hu K; Ionis Pharmaceuticals, Carlsbad, California, USA.
Brambatti M; Ionis Pharmaceuticals, Carlsbad, California, USA.
Mullick AE; Ionis Pharmaceuticals, Carlsbad, California, USA.
Geary RS; Ionis Pharmaceuticals, Carlsbad, California, USA.
Bakris GL; Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
Tsimikas S; Ionis Pharmaceuticals, Carlsbad, California, USA.

JACC Basic Transl Sci ; 6(6): 485-496, 2021 Jun.

Article en En | MEDLINE | ID: mdl-34222719

Palabras clave

ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AGT, angiotensinogen; ASO, antisense oligonucleotide; CI, confidence interval; DBP, diastolic blood pressure; EDTA, ethylenediaminetetraacetic acid; GalNAc3, triantennary N-acetyl galactosamine; K+, potassium; PS, phosphorothioate; RAAS; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure; angiotensinogen; antisense; hepatocyte; hypertension; oligonucleotide

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: JACC Basic Transl Sci Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google